Ascletis Pharma Inc.

First Subject Dosed with Gannex’s FXR Agonist ASC42 in a U.S. Phase I Trial
2020-12-28
Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial
2020-12-22
Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42，an FXR Agonist
2020-12-14
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study
2020-12-03
Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer
2020-11-30

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备 11050387号